Fiduciary Alliance LLC Makes New $4.61 Million Investment in DENTSPLY SIRONA Inc. $XRAY

Fiduciary Alliance LLC purchased a new position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) during the first quarter, Holdings Channel reports. The fund purchased 382,318 shares of the medical instruments supplier’s stock, valued at approximately $4,607,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Daiwa Securities Group Inc. grew its position in DENTSPLY SIRONA by 2.9% in the fourth quarter. Daiwa Securities Group Inc. now owns 26,814 shares of the medical instruments supplier’s stock worth $306,000 after acquiring an additional 767 shares in the last quarter. Blue Trust Inc. increased its stake in DENTSPLY SIRONA by 10.8% in the first quarter. Blue Trust Inc. now owns 12,555 shares of the medical instruments supplier’s stock valued at $146,000 after acquiring an additional 1,226 shares during the last quarter. Empowered Funds LLC raised its position in DENTSPLY SIRONA by 8.8% during the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after purchasing an additional 1,320 shares in the last quarter. Wilmington Savings Fund Society FSB lifted its stake in DENTSPLY SIRONA by 13.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 13,055 shares of the medical instruments supplier’s stock worth $149,000 after purchasing an additional 1,500 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in DENTSPLY SIRONA during the first quarter worth about $26,000. Hedge funds and other institutional investors own 95.70% of the company’s stock.

Insider Buying and Selling at DENTSPLY SIRONA

In related news, Director Brian P. Mckeon acquired 10,000 shares of the company’s stock in a transaction dated Friday, June 12th. The stock was purchased at an average price of $10.12 per share, with a total value of $101,200.00. Following the completion of the purchase, the director owned 10,000 shares in the company, valued at $101,200. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Brian T. Gladden bought 9,985 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was purchased at an average price of $10.02 per share, for a total transaction of $100,049.70. Following the acquisition, the director directly owned 61,849 shares of the company’s stock, valued at approximately $619,726.98. The trade was a 19.25% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders purchased 35,160 shares of company stock worth $351,179. 0.46% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Barclays reduced their price objective on DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a research report on Thursday, June 4th. Citigroup began coverage on DENTSPLY SIRONA in a research report on Wednesday, April 15th. They issued a “sell” rating and a $10.00 target price for the company. Zacks Research raised DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd. Mizuho reduced their price target on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Finally, Barrington Research lifted their price target on shares of DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a research note on Monday, March 2nd. Three analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $13.55.

DENTSPLY SIRONA Stock Up 3.1%

XRAY opened at $10.52 on Thursday. DENTSPLY SIRONA Inc. has a 12 month low of $9.40 and a 12 month high of $17.09. The company has a current ratio of 1.53, a quick ratio of 0.98 and a debt-to-equity ratio of 1.52. The business’s 50-day moving average price is $10.74 and its 200-day moving average price is $11.66. The company has a market cap of $2.11 billion, a P/E ratio of -3.34, a P/E/G ratio of 1.21 and a beta of 0.89.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The company had revenue of $880.00 million for the quarter, compared to analysts’ expectations of $841.80 million. During the same quarter in the prior year, the company earned $0.43 earnings per share. The company’s revenue was up .1% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, equities analysts expect that DENTSPLY SIRONA Inc. will post 1.42 EPS for the current year.

DENTSPLY SIRONA Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.